Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.60 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.58 |
| ▸ | CCR5 | P51681 | 1/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.49 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.49 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.47 |
| ▸ | KDM1A | O60341 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9133642 | 1.00 | SLC18A3 (0.60) | SLC18A3SIGMAR1CCR5EPHX2OPRM1 | |
| SCHEMBL7419921 | 1.00 | SLC18A3 (0.60) | SLC18A3SIGMAR1CCR5EPHX2OPRM1 | |
| SCHEMBL7103234 | 0.98 | SLC18A3 (0.62) | SLC18A3SIGMAR1CCR5OPRM1OPRD1 | |
| SCHEMBL6049169 | 0.94 | SIGMAR1 (0.61) | SLC18A3SIGMAR1CCR5EPHX2OPRM1 | |
| SCHEMBL5087578 | 0.92 | SIGMAR1 (0.64) | SLC18A3SIGMAR1CCR5EPHX2EPHX1 | |
| SCHEMBL11020642 | 0.92 | SIGMAR1 (0.64) | SLC18A3SIGMAR1CCR5EPHX2EPHX1 | |
| SCHEMBL7392307 | 0.92 | SIGMAR1 (0.64) | SLC18A3SIGMAR1CCR5EPHX2EPHX1 | |
| SCHEMBL11300310 | 0.92 | SIGMAR1 (0.58) | SLC18A3SIGMAR1CCR5OPRM1OPRD1 | |
| Ammonia Solution, Strong SCHEMBL20702116 | 0.92 | SLC18A3 (0.56) | SLC18A3SIGMAR1CCR5OPRM1OPRD1 | |
| SCHEMBL18435050 | 0.90 | SIGMAR1 (0.61) | SLC18A3SIGMAR1CCR5OPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2362765-A2 | PERFUME SYSTEMS | The Procter & Gamble Company (US) | 2011-09-07 | — | — | EP | claimed |
| WO-2010065446-A2 | PERFUME SYSTEMS | THE PROCTER & GAMBLE COMPANY (US) | 2010-06-10 | — | — | WO | claimed |
| US-20080076817-A1 | Small Molecule Rotamase Enzyme Inhibitors | HAMILTON GREGORY S | 2008-03-27 | — | — | US | claimed |
| EP-1227859-B1 | NEUROPHILIN LIGANDS FOR TREATING OCULAR CONDITIONS | ALCON INC (CH) | 2006-08-09 | — | — | EP | claimed |
| EP-1666037-A2 | Compositions for stimulating neurite growth | Vertex Pharmaceuticals Incorporated (US) | 2006-06-07 | — | — | EP | claimed |
| US-6943187-B2 | Pyrrolidine derivative hair growth compositions and uses | GPI NIL HOLDINGS, INC. (US) | 2005-09-13 | — | — | US | claimed |
| US-20040186098-A1 | Method for preventing and treating hearing loss using sensorineurotrophic compounds | AMGEN INC. | 2004-09-23 | — | — | US | claimed |
| US-20040049046-A1 | Small molecule inhibitors of rotamase enzyme activity | GPI NIL HOLDINGS, INC. (US) | 2004-03-11 | — | — | US | claimed |
| US-20020198250-A1 | Pyrrolidine derivative hair growth compositions and uses | GLIAMED, INC. | 2002-12-26 | — | — | US | claimed |
| US-6376517-B1 | FOR TREATING VISION LOSS, PREVENTING VISION DEGENERATION, AND PROMOTING VISION REGENERATION (?NEOPSIS?) | GPI NIL HOLDINGS, INC. | 2002-04-23 | — | — | US | claimed |
| US-20010034362-A1 | Pyrrolidine derivatives for vision and memory disorders | GUILFORD PHARMACEUTICALS INC. (US) | 2001-10-25 | — | — | US | claimed |
| US-6218423-B1 | ADMINISTERING PYRROLIDINE DERIVATIVE FOR THERAPY OF NERVE-RELATED VISION DISORDER, IMPROVING VISION, TREATING MEMORY IMPAIRMENT, OR ENHANCING MEMORY PERFORMANCE IN ANIMAL | GPI NIL HOLDINGS, INC. | 2001-04-17 | — | — | US | claimed |
| US-6177455-B1 | ADMINISTERING A NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | GPI NIL HOLDINGS, INC. | 2001-01-23 | — | — | US | claimed |
| EP-0769006-B1 | SMALL MOLECULE INHIBITORS OF ROTAMASE ENZYME ACTIVITY | GUILFORD PHARM INC (US) | 2000-11-08 | — | — | EP | claimed |
| EP-1011650-A1 | METHOD FOR PREVENTING AND TREATING HEARING LOSS USING SENSORINEUROTROPHIC COMPOUNDS | Amgen Inc., (US) | 2000-06-28 | — | — | EP | claimed |
| EP-0992492-A1 | Small molecule inhibitors of rotamase enzyme activity | GUILFORD PHARMACEUTICALS INC. (US) | 2000-04-12 | — | — | EP | claimed |
| WO-1999014998-A2 | METHOD FOR PREVENTING AND TREATING HEARING LOSS USING SENSORINEUROTROPHIC COMPOUNDS | AMGEN INC. (US) | 1999-04-01 | — | — | WO | claimed |
| US-5843960-A | Inhibitors of rotamase enzyme activity | GPI NIL HOLDINGS, INC. (US) | 1998-12-01 | — | — | US | claimed |
| US-5614547-A | Small molecule inhibitors of rotamase enzyme | GUILFORD PHARMACEUTICALS INC. (US) | 1997-03-25 | — | — | US | claimed |
| WO-1996040633-A1 | SMALL MOLECULE INHIBITORS OF ROTAMASE ENZYME ACTIVITY | GUILFORD PHARMACEUTICALS INC. (US) | 1996-12-19 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186098-A1 | Method for preventing and treating hearing loss using sensorineurotrophic compounds | GAP43, CHAT, MYOC | SLC18A3 165/4885SIGMAR1 3620/4885CCR5 2230/4885 |
| US-20040049046-A1 | Small molecule inhibitors of rotamase enzyme activity | FKBP8, FKBP14, PREP | SLC18A3 1294/4885SIGMAR1 4024/4885CCR5 2594/4885 |
| US-20020198250-A1 | Pyrrolidine derivative hair growth compositions and uses | MKI67, PLOD2, HDGF | SLC18A3 4791/4885SIGMAR1 4811/4885CCR5 2368/4885 |
| US-20010034362-A1 | Pyrrolidine derivatives for vision and memory disorders | PDE6D, PDE6C, PDE4D | SLC18A3 382/4885SIGMAR1 3400/4885CCR5 1110/4885 |
| US-20080076817-A1 | Small Molecule Rotamase Enzyme Inhibitors | FKBP8, FKBP1A, FKBP2 | SLC18A3 1479/4885SIGMAR1 4550/4885CCR5 2281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.